Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 5/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11284817 | 0.82 | CES1 (0.52) | CES1SRCMAPK1MAPTTDP1 | |
| SCHEMBL11521626 | 0.79 | CES1 (0.54) | CES1SRCMAPK1MAPTTDP1 | |
| SCHEMBL36374 | 0.78 | CES1 (0.48) | CES1SRCMAPK1MAPTTDP1 | |
| SCHEMBL8759046 | 0.78 | SRC (0.48) | CES1SRCMAPK1MAPTTDP1 | |
| SCHEMBL10471882 | 0.77 | SRC (0.47) | CES1SRCMAPK1MAPTTDP1 | |
| SCHEMBL8071585 | 0.77 | CES1 (0.47) | CES1SRCMAPK1MAPTTDP1 | |
| SCHEMBL11341422 | 0.76 | CES1 (0.56) | CES1SRCMAPTTDP1CYP3A4 | |
| SCHEMBL13044333 | 0.76 | CES1 (0.50) | CES1SRCMAPK1MAPTTDP1 | |
| SCHEMBL759622 | 0.76 | CES1 (0.50) | CES1SRCMAPK1MAPTTDP1 | |
| SCHEMBL669851 | 0.75 | CES1 (0.61) | CES1SRCMAPK1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605764-A | Carrier composition for inorganic fine particle dispersion, inorganic fine particle dispersion slurry composition, and method for producing inorganic fine particle dispersible tablet | 积水化学工业株式会社 | 2022-06-10 | — | — | CN | disclosed |
| CN-112585212-B | Carrier composition for inorganic fine particle dispersion, inorganic fine particle dispersion slurry composition, and method for producing inorganic fine particle dispersible tablet | 积水化学工业株式会社 | 2022-04-19 | — | — | CN | disclosed |
| CN-112585212-A | Carrier composition for inorganic fine particle dispersion, inorganic fine particle dispersion slurry composition, and method for producing inorganic fine particle dispersible tablet | 积水化学工业株式会社 | 2021-03-30 | — | — | CN | disclosed |
| US-20080254130-A1 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction | BIODERM RESEARCH (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080254130-A1 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction | PSMB1, PLOD3, CUTA | CES1 1542/4885SRC 3657/4885MAPK1 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.